This statistical finding supports a lower liver-weight signal after adjustment for body fat percenta

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&

ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, includin

ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, includin

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced updated preclinical data from non-GLP diet-

FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) to

Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experien

Alaunos Therapeutics Inc. (NASDAQ: TCRT) shares are down on Monday after the company announced precl

The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body compositio

Alaunos' ALN1003 shows dose dependent weight loss, better body composition, reduced liver weight, an

Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) saw a significant decline in short inter

Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) was up 3.1% during mid-day trading on We

Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names h

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores

Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.63) per share. This is a 11.27 p

HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”)

PMGC Capital LLC ("PMGC Capital"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:E

NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly

NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our

Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead an

Alaunos Therapeutics (NASDAQ: TCRT ) stock is up on Monday despite a lack of news from the clinical-

Alaunos Therapeutics (NASDAQ: TCRT ) stock is heading higher on Tuesday following the release of the

HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (

Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company w

HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (

Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earn

HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (N

HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”)

Companies Reporting Before The Bell • Cohen & Co (AMEX:COHN) is likely to report earnings for i

HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (

Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared